WARREN, N.J., Dec. 22, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) announced today that Sephience™ (sepiapterin) has been approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) ...
PTC Therapeutics (NASDAQ:PTCT) reported fourth-quarter and full-year 2025 results highlighted by the initial global approvals ...
The company narrowed its 2025 full year revenue guidance to $750 million to $800 million, attributing the upper end confidence to early Sephience results and stable DMD franchise performance. Pierre ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results